The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Einarson, A.
* Articles by Koren, G.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Einarson, A.
* Articles by Koren, G.
Related Collections
* Other Childhood Disorders
* Antidepressants
Am J Psychiatry 158:1728-1730, October 2001
© 2001 American Psychiatric Association


Brief Report

Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study

Adrienne Einarson, R.N., Bumn Fatoye, M.D., Moumita Sarkar, B.Sc., Sharon Voyer Lavigne, M.Sc., Joanne Brochu, Christina Chambers, M.P.H., Pierpaolo Mastroiacovo, M.D., Antonio Addis, Pharm.D., Doreen Matsui, M.D., Lavinia Schuler, M.D., M.Sc., Thomas R. Einarson, Ph.D., and Gideon Koren, M.D.

OBJECTIVE: Because there are no studies available on the safety of venlafaxine during pregnancy, the authors’ goal in this study was to determine whether venlafaxine increases the risk for major malformations. METHOD: Data on 150 women exposed to venlafaxine during pregnancy in seven pregnancy counseling centers were compared with data from studies of pregnant women who 1) received selective serotonin reuptake inhibitor antidepressants (SSRIs) (N=150) and 2) who received nonteratogenic drugs (N=150). RESULTS: Among the 150 women who were exposed to venlafaxine during pregnancy, 125 had live births, 18 had spontaneous abortions, and seven had therapeutic abortions; two of the babies had major malformations. There were no significant differences between these women and the two comparison groups on any of the measures analyzed. CONCLUSIONS: These results suggest that the use of venlafaxine during pregnancy does not increase the rates of major malformations above the baseline rate of 1%–3%.




This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
A. Einarson, A. Pistelli, M. DeSantis, H. Malm, W. D. Paulus, A. Panchaud,, D. Kennedy, T. R. Einarson, and G. Koren
Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy
Am J Psychiatry, June 1, 2008; 165(6): 749 - 752.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
E. Ferreira, A. M. Carceller, C. Agogue, B. Z. Martin, M. St-Andre, D. Francoeur, and A. Berard
Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
Pediatrics, January 1, 2007; 119(1): 52 - 59.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
T. F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman
Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.
Arch Gen Psychiatry, August 1, 2006; 63(8): 898 - 906.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. L. Moses-Kolko, D. Bogen, J. Perel, A. Bregar, K. Uhl, B. Levin, and K. L. Wisner
Neonatal Signs After Late In Utero Exposure to Serotonin Reuptake Inhibitors: Literature Review and Implications for Clinical Applications
JAMA, May 18, 2005; 293(19): 2372 - 2383.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. E. Hemels, A. Einarson, G. Koren, K. L Lanctot, and T. R Einarson
Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis
Ann. Pharmacother., May 1, 2005; 39(5): 803 - 809.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
T. F. Oberlander, R. E. Grunau, C. Fitzgerald, M. Papsdorf, D. Rurak, and W. Riggs
Pain Reactivity in 2-Month-Old Infants After Prenatal and Postnatal Selective Serotonin Reuptake Inhibitor Medication Exposure
Pediatrics, February 1, 2005; 115(2): 411 - 425.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
G. Koren
Discontinuation Syndrome Following Late Pregnancy Exposure to Antidepressants
Arch Pediatr Adolesc Med, April 1, 2004; 158(4): 307 - 308.
[Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
D. Kohen
Psychotropic medication in pregnancy
Advan. Psychiatr. Treat., January 1, 2004; 10(1): 59 - 66.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
V. Hendrick and L. Altshuler
Management of Major Depression During Pregnancy
Am J Psychiatry, October 1, 2002; 159(10): 1667 - 1673.
[Full Text] [PDF]


Home page
JWatch Women's HealthHome page
Venlafaxine in Pregnancy: Cautious Optimism
Journal Watch Women's Health, December 17, 2001; 2001(1217): 4 - 4.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org